On 2 September 2026, Jinxin Fertility Group Limited (JXR) repurchased 1.37 million ordinary shares on the Hong Kong Stock Exchange, paying an aggregate HK$3.00 million. The shares were acquired within a price range of HK$2.165–2.24, translating into a volume-weighted average cost of HK$2.1877 per share.

Following the buyback: • Issued shares (excluding treasury shares) declined by 1.37 million, or 0.05%, to 2.70 billion. • Treasury shares increased from 8.01 million to 9.38 million. • Total issued shares remained unchanged at 2.71 billion, as the repurchased stock is being held in treasury.

Ongoing cancellation pipeline Separate from treasury movements, JXR has 32 tranches of repurchased shares—acquired between 27 March and 25 August 2026—awaiting formal cancellation. These purchases, executed at volume-weighted average prices ranging from HK$1.97 to HK$2.47 per share, collectively remain classified as issued but will be removed from share capital once cancelled.

Repurchase mandate utilisation Shareholders approved a mandate on 25 June 2026 authorising the company to repurchase up to 262.51 million shares. As of the latest transaction, 21.92 million shares, equal to 0.84% of the company’s outstanding shares on the mandate date, have been bought back under this authority. In line with Hong Kong Stock Exchange rules, JXR is subject to a 30-day moratorium on issuing new shares or disposing of treasury stock, effective until 2 October 2026.

Strategic considerations The incremental reduction in outstanding shares and accumulation of treasury stock suggest continued execution of the approved buyback strategy. Investors will monitor subsequent filings for confirmation of future cancellations and additional repurchase activity, which could further influence per-share metrics.